A case of advanced pancreatic cancer responding to combination chemotherapy with the individual maximum repeatable dose of gemcitabine and oral S-1

Chinatsu Fujimoto; Yuji Maruyama; Yuusuke Niina; Nao Fujimori; Toshihiko Sumii; Akihiro Funakoshi

A case of advanced pancreatic cancer responding to combination chemotherapy with the individual maximum repeatable dose of gemcitabine and oral S-1

Chinatsu Fujimoto, Yuji Maruyama, Yuusuke Niina, Nao Fujimori, Toshihiko Sumii, Akihiro Funakoshi

Department of Hepatology and Pancreatology

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The patient was a 70-year-old man with metastatic pancreatic cancer. After he received combination chemotherapy with gemcitabine and oral S-1 on day 1, he experienced severe general fatigue, anorexia and nausea. Then we changed the dose of gemcitabine from 1,000 mg/m(2) 2 to 500 mg/m(2) according to the criteria for an individual maximum repeatable dose (iMRD) determination method on day 8. His general condition recovered, and treatment schedule of gemcitabine with S-1 was continued sequentially at an outpatient clinic. His tumor marker levels, and the sizes of primary pancreatic tumor and liver metastatic lesions remarkably decreased. Partial response has been obtained for 7 months.

Original language	English
Pages (from-to)	1013-1016
Number of pages	4
Journal	Gan to kagaku ryoho. Cancer & chemotherapy
Volume	35
Issue number	6
Publication status	Published - Jan 1 2008

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{9b2f51da3d854a0c9d85a327349d8dcf,

title = "A case of advanced pancreatic cancer responding to combination chemotherapy with the individual maximum repeatable dose of gemcitabine and oral S-1",

abstract = "The patient was a 70-year-old man with metastatic pancreatic cancer. After he received combination chemotherapy with gemcitabine and oral S-1 on day 1, he experienced severe general fatigue, anorexia and nausea. Then we changed the dose of gemcitabine from 1,000 mg/m(2) 2 to 500 mg/m(2) according to the criteria for an individual maximum repeatable dose (iMRD) determination method on day 8. His general condition recovered, and treatment schedule of gemcitabine with S-1 was continued sequentially at an outpatient clinic. His tumor marker levels, and the sizes of primary pancreatic tumor and liver metastatic lesions remarkably decreased. Partial response has been obtained for 7 months.",

author = "Chinatsu Fujimoto and Yuji Maruyama and Yuusuke Niina and Nao Fujimori and Toshihiko Sumii and Akihiro Funakoshi",

year = "2008",

month = jan,

day = "1",

language = "English",

volume = "35",

pages = "1013--1016",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "6",

}

TY - JOUR

T1 - A case of advanced pancreatic cancer responding to combination chemotherapy with the individual maximum repeatable dose of gemcitabine and oral S-1

AU - Fujimoto, Chinatsu

AU - Maruyama, Yuji

AU - Niina, Yuusuke

AU - Fujimori, Nao

AU - Sumii, Toshihiko

AU - Funakoshi, Akihiro

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The patient was a 70-year-old man with metastatic pancreatic cancer. After he received combination chemotherapy with gemcitabine and oral S-1 on day 1, he experienced severe general fatigue, anorexia and nausea. Then we changed the dose of gemcitabine from 1,000 mg/m(2) 2 to 500 mg/m(2) according to the criteria for an individual maximum repeatable dose (iMRD) determination method on day 8. His general condition recovered, and treatment schedule of gemcitabine with S-1 was continued sequentially at an outpatient clinic. His tumor marker levels, and the sizes of primary pancreatic tumor and liver metastatic lesions remarkably decreased. Partial response has been obtained for 7 months.

AB - The patient was a 70-year-old man with metastatic pancreatic cancer. After he received combination chemotherapy with gemcitabine and oral S-1 on day 1, he experienced severe general fatigue, anorexia and nausea. Then we changed the dose of gemcitabine from 1,000 mg/m(2) 2 to 500 mg/m(2) according to the criteria for an individual maximum repeatable dose (iMRD) determination method on day 8. His general condition recovered, and treatment schedule of gemcitabine with S-1 was continued sequentially at an outpatient clinic. His tumor marker levels, and the sizes of primary pancreatic tumor and liver metastatic lesions remarkably decreased. Partial response has been obtained for 7 months.

UR - http://www.scopus.com/inward/record.url?scp=48249119660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249119660&partnerID=8YFLogxK

M3 - Article

C2 - 18633236

AN - SCOPUS:48249119660

SN - 0385-0684

VL - 35

SP - 1013

EP - 1016

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 6

ER -

A case of advanced pancreatic cancer responding to combination chemotherapy with the individual maximum repeatable dose of gemcitabine and oral S-1

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this